切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2017, Vol. 11 ›› Issue (01) : 51 -55. doi: 10.3877/cma.j.issn.1674-0793.2017.01.014

所属专题: 文献

综述

结直肠癌肝转移的治疗现状
王盛1, 喻春钊1,()   
  1. 1. 210011 江苏省南京医科大学第二附属医院普外科
  • 收稿日期:2016-09-27 出版日期:2017-02-01
  • 通信作者: 喻春钊
  • 基金资助:
    国家自然科学基金面上项目(30972910,81172269); 江苏省自然科学基金资助项目(BK2011858); 江苏省六大人才高峰基金资助项目(WSW-032)

Current therapeutic options for colorectal liver metastases

Sheng Wang1, Chunzhao Yu1,()   

  1. 1. Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
  • Received:2016-09-27 Published:2017-02-01
  • Corresponding author: Chunzhao Yu
  • About author:
    Corresponding author: Yu Chunzhao, Email:
引用本文:

王盛, 喻春钊. 结直肠癌肝转移的治疗现状[J]. 中华普通外科学文献(电子版), 2017, 11(01): 51-55.

Sheng Wang, Chunzhao Yu. Current therapeutic options for colorectal liver metastases[J]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(01): 51-55.

肝脏是结直肠癌最常见的远处侵犯器官。目前肝切除是治疗结直肠癌肝转移(CLM)安全、有效且唯一有治愈可能的方法,且大于50%的患者术后可以获得5年生存。近年来,化疗、消融术、放射治疗等技术的不断完善,在一定程度上提高了国内外结直肠癌肝转移的诊疗水平。合理地联合应用这些疗法制定综合的治疗方案,对CLM患者的预后有着深远的影响。现就CLM的治疗现状作一综述。

Colorectal cancer is one of the most common malignant tumors, with its distant metastasis mainly to the liver. Currently, hepatectomy is the only safe and effective measure to cure colorectal liver metastasis (CLM), providing more than 50% 5-year-survival after the operation. In recent years, the diagnosis and treatment of CLM has been elevated with the improvement of chemotherapy, ablation, and radiotherapy. Comprehensive therapeutic schedule designed by appropriately integrating all the above-mentioned treatments exerts profound impact on the prognosis of CLM patients. This review attempts at summarizing the present status of CLM treatment.

表1 结直肠癌肝转移的网格分期系统
图1 可切除结直肠癌肝转移患者的治疗流程图
[1]
Siegel R,Naishadham D,Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2]
Biasco G,Derenzini E,Grazi G, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties[J]. Cancer Treat Rev, 2006, 32(3): 214-228.
[3]
Jönsson K,Gröndahl G,Salö M, et al. Repeated liver resection for colorectal liver metastases: a comparison with primary liver resections concerning perioperative and long-term outcome[J]. Gastroenterol Res Pract, 2012, 2012: 568214.
[4]
Adam R,Hoti E,Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?[J]. J Surg Oncol, 2010, 102(8): 922-931.
[5]
中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2015版)[J/CD]. 中华普通外科学文献(电子版), 2015, 9(6): 506-523.
[6]
Hughes KS,Simon R,Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence[J]. Surgery, 1986, 100(2): 278-284.
[7]
Pawlik TM,Scoggins CR,Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 715-722.
[8]
Yoo PS,Lopez-Soler RI,Longo WE, et al. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab[J]. Clin Colorectal Cancer, 2006, 6(3): 202-207.
[9]
Poston GJ,Figueras J,Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer[J]. J Clin Oncol, 2008, 26(29): 4828-4233.
[10]
林俊忠,潘志忠. 结直肠癌肝转移外科治疗的争议[J]. 中华胃肠外科杂志, 2013, 16(8): 714-716.
[11]
李宇杰,车向明,甘建新, 等. 同时性结直肠癌肝转移同期与分期手术疗效的Meta分析[J]. 西安交通大学学报:医学版, 2012, 33(3): 365-369.
[12]
Cleary JM,Tanabe KT,Laywer GY, et al. Hepatic toxicities associated with the use of preoprative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver[J]. Oncologist, 2009, 14(11): 1095-1105.
[13]
吕文平,崔晓峰,蔡守旺, 等. 术中超声辅助肝切除联合射频消融根治性治疗双叶弥散性结直肠癌肝转移[J/CD]. 中华普外科手术学杂志(电子版)2012, 6(2): 21-23.
[14]
中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠肛门外科学组, 中国抗癌协会大肠癌专业委员会, 等. 结直肠癌肝转移诊断和综合治疗指南(2016版)[J]. 中华消化外科杂志, 2016, 15(8): 755-767.
[15]
Waisberg J,Ivankovics IG. Liver-first approach of colorectal cancer with synchronous hepatic metastases: a reverse strategy[J]. World J Hepatol, 2015, 7(11): 1444-1449.
[16]
常颜信,杨家和. 结直肠癌肝转移的外科治疗现状与进展[J]. 国际外科学杂志, 2010, 37(2): 105-108.
[17]
Jones RP,Jackson R,Dunne DF, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases[J]. Br J Surg, 2012, 99(4): 477-486.
[18]
Rolff HC,Calatayud D,Larsen PN, et al. Good results after repeated resection for colorectal liver metastases[J]. Dan Med J, 2012, 59(2): A4373.
[19]
刘伟,闫晓峦,王崑, 等. 结直肠癌肝转移二次切除的预后分析[J]. 中华医学杂志, 2013, 93(28): 2183-2185.
[20]
Oussoultzoglou E,Romain B,Panaro F, et al. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens[J]. Ann Surg, 2009, 249(6): 879-886.
[21]
Pulitanò C,Bodingbauer M,Aldrighetti L, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection[J]. Ann Surg Oncol, 2012, 19(2): 435-442.
[22]
Wang DS,Louie JD,Sze DY. Intra-arterial therapies for metastatic colorectal cancer[J]. Semin Intervent Radiol, 2013, 30(1): 12-20.
[23]
Lordan JT,Karanjia ND,Quiney N, et al. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting[J]. Eur J Surg Oncol, 2009, 35(3): 302-306..
[24]
徐达,邢宝才. 结直肠癌肝转移外科治疗策略[J]. 中国肿瘤临床, 2015, 42(17): 845-849.
[25]
Zdenkowski N,Chen S,van der Westhuizen A, et al. Curative strategies for liver metastases from colorectal cancer: a review[J]. Oncologist, 2012, 17(2): 201-211.
[26]
Cai GX,Cai SJ. Multi-modality treatment of colorectal liver metastases[J]. World J Gastroenterol, 2012, 18(1): 16-24.
[27]
乔天宇,徐永鹏,关旭, 等. 结直肠癌肝转移的治疗及预后因素分析[J]. 中华胃肠外科杂志, 2015, 18(9): 930-934.
[28]
National Comprehensive Cancer Network. The NCCN colorectal Cancer clinical practice guidelines in oncology (version 2.2016)[EB/OL]. [2016-09-27].

URL    
[29]
Khan K,Wale A,Brown G, et al. Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?[J]. World J Gastroenterol, 2014, 20(35): 12391-12406.
[30]
Bismuth H,Adam R,Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy[J]. Ann Surg, 1996, 224(4): 509-520.
[31]
Folprecht G,Gruenberger T,Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47.
[32]
Loupakis F,Cremolini C,Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J]. N Engl J Med, 2014, 371(17): 1609-1618.
[33]
姚陈果,赵亚军,李成祥, 等. 不可逆电穿孔微创消融肿瘤技术的研究进展[J]. 高压电技术, 2014, 40(12): 3725-3737.
[34]
Ball C,Thomson KR,Kavnoudias H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia[J]. Anesth Analg, 2010, 110(5): 1305-1309.
[35]
Joosten J,Ruers T. Local radiofrequency ablation techniques for liver metastases of colorectal cancer[J]. Crit Rev Oncol Hematol, 2007, 62(2): 153-163.
[36]
Wood TF,Rose DM,Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications[J]. Ann Surg Oncol, 2000, 7(8): 593-600.
[37]
Dodd GD 3rd,Frank MS,Aribandi M, et al. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations[J]. AJR Am J Roentgenol, 2001, 177(4): 777-782.
[38]
Nosher JL,Ahmed I,Patel AN, et al. Non-operative therapies for colorectal liver metastases[J]. J Gastrointest Oncol, 2015, 6(2): 224-240.
[39]
赵明,王健鹏,吴沛宏, 等. 射频消融治疗结直肠癌肝转移及其预后因素分析[J]. 中华医学杂志, 2010, 90(23): 1587-1592.
[40]
Chu KF,Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3): 199-208.
[41]
Correa-Gallego C,Fong Y,Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases[J]. Ann Surg Oncol, 2014, 21(13): 4278-4283.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[5] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[6] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[7] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[8] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[9] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[10] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[11] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[12] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[13] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[14] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[15] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
阅读次数
全文


摘要